| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, City Therapeutics, Inc.'s insiders have accumulated 340,000 shares worth roughly $6.1M on balance. In the past 30 days, 2 insiders bought and 0 sold. Recent activity has leaned to the buy side.
The largest recent buyer is ARCH Venture Partners XII, LLC (10% Owner).
CTY sits in the Biotechnology industry within the Healthcare sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 6.01M | - | +170.0K | |
| 10% | 6.01M | - | +170.0K | |
| CEO | 78.0K | - | - | |
| Dir | 22.6K | - | - | |
| Dir | 22.6K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | Arch Venture Partners Xii, LLC62 | 10% Owner | Buy | 170,000 | $18.00 | $3,060,000.00 | +1.3% | |
| Oct 19, 2026 | Nelsen Robert | Director, 10% Owner | Buy | 170,000 | $18.00 | $3,060,000.00 | +1.3% |